© Fraunhofer ITMP

Repurposing as a strategy in the fight against COVID-19

Testing existing drugs for additional indications is a promising approach to find drugs for COVID-19 patients as quickly as possible. For this purpose we use the Fraunhofer ITMP Repurposing Collection.

more info

Fraunhofer vs. Corona

Find out how Fraunhofer experts are contributing to the fight against the pandemic.

more info
© Fraunhofer ITMP | Alena Grebe

Health Research in 4D

Fraunhofer ITMP conducts health research in line with the Fraunhofer 4D-Concept.

© Fotolia

Fraunhofer CIMD

Fraunhofer ITMP is a core institute of the Fraunhofer Cluster of Excellence Immune-Mediated Diseases.

more info

Research Divisions

Fraunhofer ITMP is organized in 3 cross-site research divisions.


Drug Discovery


From target to screening to lead optimization and formulation.


Preclinical Research


From translational target- and drug-validation to retranslational OMICs-analyses of patient samples for characterization of biological processes and identification of novel targets.


Clinical Research


From early „Proof-of-Concept“ to the characterization of approved products: “Quality by Design” as key to successful translation of innovative ideas to the patient.

Innovation Areas

Fraunhofer ITMP is optimally interconnected internally as well as externally with other Fraunhofer institutes, universities and industry via the innovation areas. This is the prerequisite for transdisciplinary and flexible cooperation in the areas of new technologies, disease and treatment concepts.



Further Notifications

Here you find all press releases and further notifications, as well as all events of Fraunhofer ITMP.

Press Release / 1.9.2021

Fraunhofer ITMP spin-off “Phialogics” founded


In August 2021, after several years of research at Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, a team of scientists has spun-off and created Phialogics, a preclinical-stage biotechnology company dedicated to the development of innovative biologics to treat autoimmune diseases.

News / 12.8.2021

Fraunhofer ITMP employee worldwide "psoriatic arthritis expert"


PD Dr. Frank Behrens, Deputy Director of Fraunhofer ITMP and Head of the Clinical Research division, is listed as an expert in psoriatic arthritis on the Expertscape expert platform. This places him in the top 1% of scientists worldwide who have written on the topic of psoriatic arthritis in the last 10 years. 

Expertscape uses PubMed-based algorithms to objectively rank individuals and institutions according to their expertise in more than 29,000 biomedical topics.

Press Release / 2.7.2021

"HIPPOCRATES" helps patients with psoriasis arthritis


Fraunhofer CIMD in leading role in new EU-IMI project "HIPPOCRATES" to promote early detection and improve outcome of psoriatic arthritis.

Funded by the Innovative Medicines Initiative (IMI), Fraunhofer ITMP, IAIS and IGD, as part of the Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, are collaborating with 25 European partners to research an insufficiently understood disease that affects millions of people.

Events / 12.11.2021

3rd Fraunhofer CIMD "Day of Immune Research"


Fraunhofer ITMP is one of the core institutes of the Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD. The annual "Day of Immune Research" provides insights into the work of the cluster and serves as an information and exchange platform for current topics in the field of immune-mediated diseases and immune research. 

The 3rd Day of Immune Research will take place in a digital format on November 12, 2021. 

Events / 5.10.2021

Fraunhofer CIMD Winter School 2021


The Fraunhofer CIMD Winter School will take place from October 5-8, 2021 in a virtual format as part of the Fraunhofer CIMD Young Investigator Program. This event is primarily aimed at PhD students, young postdocs and project members from the Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, of which Fraunhofer ITMP is a core institute.

News / 12.5.2021

Drug Repurposing as strategy in the fight against COVID-19


After the recent successes in vaccine development, drug development against the COVID-19 disease is moving into focus. Fraunhofer ITMP is applying Drug Repurposing strategies in various projects focusing on SARS-CoV-2. Repurposing strategies use substances that have undergone clinical testing in other disease indications and investigate their effect against COVID-19. These strategies can not only identify effective substances for different stages of the disease, but also contribute to a better understanding of the mechanisms of action of this disease.